Anthracyclines as Tumor Cell Differentiating Agents: Effects on the Regulation of Erythroid Gene Expression

References

• Sachs L. Control of normal cell differentiation and phenotypic reversion of malignancy in myeloid leukemia. Nature 1978; 274: 535–539
   PubMed Web of Science ®Google Scholar
• Reiss M., Gamba-Vitalo C., Sartorelli A. C. Induction of tumor cell differentiation as a therapeutic approach: preclinical models for hematopoietic and solid neoplasms. Cancer Treat. Rep. 1986; 70: 201–218
   PubMedGoogle Scholar
• Degos L., Dombret H., Chomienne C., Daniel M. T., MiclÉA J. M., Chastang C., Castaigne S., Fenaux P. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995; 85: 2643–2653
   PubMed Web of Science ®Google Scholar
• Newmark H. L., Young C. W. Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. J. Cell. Biochem. 1995; 22: 247–253, suppl
   Google Scholar
• Sehested M., Buhl Jensen P. Mapping of DNA topoisomerase II poisons (Etoposide, Clerocidin) and catalytic inhibitors (Aclarubicin, ICW-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem. Pharmacol. 1996; 51: 879–886
   PubMed Web of Science ®Google Scholar
• Keizer H. G., Pinedo H. M., Schuurhuis G. J., Joenje H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol. Ther. 1990; 47: 219–231
   PubMed Web of Science ®Google Scholar
• Papadopoulou L. C., Tsiftsoglou A. S. Mitochondrial cytochrome c oxidase as a target site for dauno-mycin in K-562 cells and heart tissue. Cancer Res. 1993; 53: 1072–1078
   PubMed Web of Science ®Google Scholar
• Arancia G., Bordi F., Calcabrini A., Diociaiuti M., Molinari A. Ultrastructural and spectroscopic methods in the study of anthracycline-membrane interaction. Pharmacol. Res. 1995; 32: 255–272
   PubMed Web of Science ®Google Scholar
• Steinheider G., Westendorf J., Marquardt H. Induction of erythroid differentiation by the anthracycline antitumor antibiotics, aclacinomycin A, musettamycin and marcellomycin. Leuk. Res. 1986; 10: 1233–1239
   PubMed Web of Science ®Google Scholar
• Schwartz E. L., Sartorelli A. C. Structure-activity relationships for the induction of differentiation of HL-60 human acute promyelocytic leukemia cells by anthracyclines. Cancer Res 1982; 42: 2651–2655
   PubMed Web of Science ®Google Scholar
• Morin M. J., Sartorelli A. C. Inhibition of glyco-protein biosynthesis by the inducers of HL-60 cell differentiation, aclacinomycin A and marcellomycin. Cancer Res. 1984; 44: 2807–2812
   PubMed Web of Science ®Google Scholar
• Jeannesson P., Ginot L., Manfait M., Jardillier J. C. Induction of hemoglobin synthesis in human leukemic K 562 cells by adriamycin. Anticancer Res. 1984; 4: 47–52
   PubMed Web of Science ®Google Scholar
• Mazouzi Z., Francastel C., Tapiero H., Robert-Lbzbnbs J. Growth inhibition of doxorubicin-resis-tant K562 leukemia cells by anthracyclines: absence of correlation with erythroid differentiation. J. Cell. Pharmacol. 1991; 2: 157–164
   Google Scholar
• Nakamura K., Okano H., Kaku M., Motomura S. In vitro differentiation of a human erythroid cell line (KMOE) induced by some metabolic inhibitors. J. Cancer Res. Clin. Oncol. 1985; 110: 203–208
   PubMed Web of Science ®Google Scholar
• Bloch A. Dynamics of interaction between DNA-spe-cific antitumor agents and serum-contained cytokines in the initiation of ML-1 human myeloblastic leukemia cell differentiation. Leukemia 1993; 7: 1219–1224
   PubMed Web of Science ®Google Scholar
• Gamba-Vitalo C., Blair O. C., Keyes S. R., Sartorelli A. C. Differentiation of WEHI3B D+ monomyelocytic leukemia cells by retinoic acid and aclacinomycin A. Cancer Res. 1986; 46: 1189–1194
   PubMed Web of Science ®Google Scholar
• Gamba-Vitalo C., Blair O. C., Tritton T. R., Lane P. A., Carbone R., Sartorelli A. C. Cytotoxicity and differentiating actions of adriamycin in WEHI-3B D+ leukemia cells. Leukemia 1987; 1: 188–197
   PubMed Web of Science ®Google Scholar
• Raz A. B16 melanoma cell variants: irreversible inhibition of growth and induction of morphologic differentiation by anthracycline antibiotics. J. Natl. Cancer Inst. 1982; 68: 629–638
   PubMed Web of Science ®Google Scholar
• Supino R., Mariani M., Colombo A., Prosperi E., Croce A. C., Bottiroli G. Comparative studies on the effects of doxorubicin and differentiation inducing agents on B16 melanoma cells. Eur. J. Cancer 1992; 28, A, 778–783.
   PubMedGoogle Scholar
• Prasad K. N., Edwards-Prasad J., Ramanujam S., Sakarnoto A. Vitamin E increases the growth inhibitory and differentiating effects of therapeutic agents on neuroblastoma and glioma cells in culture. Proc. Soc. Exp. Biol. Med. 1980; 164: 158–163
   PubMed Web of Science ®Google Scholar
• Schengrund C. L., Scheffler B. A. Biochemical and morphological study of adriamycin-induced changes in murine neuroblastoma cells. Oncology 1982; 39: 185–190
   PubMed Web of Science ®Google Scholar
• Lollini P. L., De Giovanni C., Del Re B., Landuzzi L., Nicoletti G., Prodi G., Scotlandi K., Nanni P. Myogenic differentiation of human rhabdomyosarcoma cells induced in vitro by antineoplastic drugs. Cancer Res. 1989; 49: 3631–3636
   PubMed Web of Science ®Google Scholar
• Rocchi P., Ferreri A. M., Simone G., Prodi G. Epirubicin-induced differentiation of human neuroblastoma cells in vitro. Anticancer Res. 1987; 7: 247–250
   PubMed Web of Science ®Google Scholar
• Casazza A. M. Anthracyclines as inducers of tumor cell differentiation. Bioactive Molecules, J. W. Lown. Amsterdam, Elsevier 1988; 715–734
   Google Scholar
• Sakurai M., Sampi K., Hozumi M. Possible differentiation of human acute rnyeloblastic leukemia cells by daily and intermittent administration of aclacinomycin-A. Leuk. Res. 1983; 7: 139–143
   PubMed Web of Science ®Google Scholar
• Sato S., Sakashita A., Ishiyama T., Nakamaki T., Hino K. I., Tomoyasu S., Tsuruoka N., Homma Y., Hozumi M. Possible differentiation treatment with aclacinomycin A in acute myelomonocytic leukemia refractory to conventional chemotherapy. Anticancer Res. 1992; 12: 311–376
   Google Scholar
• Ogawa K., Tashima M., Takeda Y., Sawai H., Toi T., Sawada H., Maruyama Y., Okuma M. Erythroid differentiation and growth inhibition of K562 cells by 2′,5′-dideoxyadenosine: synergism with interferon-α. Leuk. Res. 1995; 19: 749–755
   PubMed Web of Science ®Google Scholar
• Murray N. R., Baumgardner G. P., Burns D. J., Fields A. P. Protein kinase C isotypes in human ery-throleukemia (K562) cell proliferation and differentiation. Evidence that βII protein kinase C is required for proliferation. J. Biol. Chem. 1993; 268: 15847–15853
   PubMed Web of Science ®Google Scholar
• Hoffman R., Newlands E. S. Role of protein kinase C in adriamycin-induced erythroid differentiation of K562 cells. Cancer Chemother. Pharmacol. 1991; 28: 102–104
   PubMed Web of Science ®Google Scholar
• Schaefer A., Dahle M., Radenz G., Steinheider G., Marquardt H. Structure-activity relationship between anthracycline-induced differentiation and inhibition of glyco-protein synthesis in Friend erythroteukemia cells. Leukemia 1991; 5: 95–100
   PubMed Web of Science ®Google Scholar
• Schaefer A., Dressel A., Lingelbach K., Schmidt C. A., Steinheider G., Marquardt H. Induction of differentiation in Friend-erythroleukemia cells by aclacinomycin A: early transient decrease in c-myc and c-myb mRNA levels. Leukemia 1992; 6: 828–833
   PubMed Web of Science ®Google Scholar
• Mazouzi Z., Franscastel C., Castagna M., Robert-LÉZÉNÈS J. Protooncogene expression in response to anticancer drugs in K562 leukemia cells: relationship to growth inhibition and erythroid differentiation. Mol. Cell. Diff. 1995; 3: 73–89
   Google Scholar
• Stocker U., Schaefer A., Marquardt H. DMSO-like rapid decrease in c-myc and c-myb mRNA levels and induction of differentiation in HL-60 cells by the anthracyline antitumor antibiotic aclarubicin. Leukemia 1995; 9: 146–154
   PubMed Web of Science ®Google Scholar
• Lozzio B. B., Lozzio C. B. Properties and usefulness of the original K562 human myelogenous leukemia cell line. Leuk. Res. 1979; 3: 363–370
   PubMed Web of Science ®Google Scholar
• Green A. R., Rockman S., Deluca E., Begley C. G. Induced myeloid differentiation of K562 cells with downregulation of erythroid and megakaryocytic transcription factors: a novel experimental model for hemopoietic lineage restriction. Exp. Hematol. 1993; 21: 525–531
   PubMed Web of Science ®Google Scholar
• Benoist H., ComoË L., Joly P., Carpentier Y., Desplaces A., Dufer J. Comparative effects of fagaronine, adri-amycin and aclacinomycin on K562 cell sensitivity to natural-killer-mediated lysis. Cancer Immunol. Immunother. 1989; 30: 289–294
   PubMed Web of Science ®Google Scholar
• Gigli M., Doglia S. M., Millot J. M., Valentini L., Manfait M. Quantitative study of doxorubicin in living cell nuclei by microspectrofluorometry. Biochim. Biophys. Acta. 1988; 950: 13–20
   PubMed Web of Science ®Google Scholar
• Millot J. M., Rasoanaivo T. D. W., Morjani H., Manfait M. Role of aclacinomycin A-doxorubicin association in reversal of doxorubicin resistance in K562 tumor cells. Br. J. Cancer 1989; 60: 678–684
   PubMed Web of Science ®Google Scholar
• Ngo-Nyoung M., Trentesaux C., Aries A., Carpentier Y., Jardillier J. C., Gorisse M. C., Jeannesson P. Effect of aclacinomycin-doxorubicin association on differentiation and growth of human erythroleukemic K562 cells. Anticancer Res. 1994; 14: 1203–1208
   PubMed Web of Science ®Google Scholar
• Jeannesson P., Trentesaux C., GÉRard B., Jardillier J. C., Ross K. L., TÖKÉS Z. A. Induction of erythroid differentiation in human leukemic K 562 cells by membrane-directed action of adriamycin covalently bound to rnicros-pheres. Cancer Res. 1990; 50: 1231–1236
   PubMed Web of Science ®Google Scholar
• Broglio C., Dufer J., Joly P., Carpentier Y., Desplaces A. Quantitative morphological assessment of ery-throblastic differentiation induced, in vitro, in human K562 leukemic cells. Anal. Cell. Pathol 1993; 5: 135–146
   PubMedGoogle Scholar
• Jaffrézou J. P., Levade T., BettaÏEb A., Andrieu N., Bezombes C., Maestre N., Vermeersch S., Rousse A., Laurent G. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingornyelin hydrolysis. EMBO J. 1996; 15: 2417–2424
   PubMed Web of Science ®Google Scholar
• McGahon A., Bissonnette R., Schmitt M., Cotter K. M., Green D. R., Cotter T. G. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 83: 1179–1187
   PubMed Web of Science ®Google Scholar
• Martin S. J., Lennou S. V., Bonham A. M., Cotter T. G. Induction of apoptosis (programmed cell death) in human leukemic HL-60 cells by inhibition of RNA or protein synthesis. J. Immunol. 1990; 145: 1859–1867
   PubMed Web of Science ®Google Scholar
• Papadopoulou L. C., Tsifsoglou A. S. Effects of hemin on apoptosis, suppression of cytochrome C oxidase gene expression, and bone-marrow toxicity induced by doxorubicin (adriamycin). Biochem. Pharmacol. 1996; 52: 713–722
   PubMed Web of Science ®Google Scholar
• Morceau F., Aries A., Lahlil R., Devy L., Jardillier J. C., Jeannesson P., Trentesaux C. Evidence for distinct regulation processes in the aclacinomycin- and doxoru-bicin-mediated differentiation of human erythroleukemic cells. Biochem. Pharmacol. 1996; 51: 839–845
   PubMed Web of Science ®Google Scholar
• Kawasaki N., Morimoto K., Tanimoto T., Hayakaw T. Control of hemoglobin synthesis in erythroid differentiating K562 cells. Role of iron in erythroid cell heme synthesis. Arch. Biochem. Biophys. 1996; 328: 289–294
   PubMed Web of Science ®Google Scholar
• Fordis M., Anagnou N. P., Dean A., Nienhuis A., Schechter A. A P-globin gene, inactive in the K562 leukemic cell, functions normally in a heterologous expression system. Proc. Natl. Acad. Sci. USA 1984; 81: 4485–4488
   PubMed Web of Science ®Google Scholar
• Jeannesson P., Trentesaux C., Ngo Nyoung M., Mayeux P., Jacquot R., Jardillier J. C. Induction of erythro-poietin receptors during aclacinomycin-mediated erythroid differentiation of K562 leukemia cells. Leukemia 1991; 5: 14–18
   PubMed Web of Science ®Google Scholar
• Kubota Y., Tanaka T., Yamaoka G., Yamaguchi M., Ohnishi H., Kawanishi K., Takahara J., Irino S. Wortmannin, a specific inhibitor of phosphatidylinositol-3-kinase, inhibits erythropoietin-induced erythroid differentiation of K562 cells. Leukemia 1996; 10: 720–726
   PubMed Web of Science ®Google Scholar
• Adunyah S. E., Ceesay K. J., Rivero J. A. Regulation of jun expression and activation of AP-1 activity by erythropoietin. Biochem. Biophys. Res. Commun. 1996; 221: 213–218
   PubMed Web of Science ®Google Scholar
• Pevny L., Simon M. C., Robertson E., Klein W. H., Tsai S. F., D'Agati V., Orkin S. H., Costantini F. Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1. Nature 1991; 349: 257–260
   PubMed Web of Science ®Google Scholar
• Andrews N. C., Kotkow K. J., Ney P. A., Erdjument-Bromage H., Tempst P., Orkin S. H. The ubiquitous subunit of erythroid transcription factor NF-E2 is as small basic-leucine zipper protein related to the v-maf oncogene. Proc. Natl. Acad. Sci. USA 1993; 90: 11488–11492
   PubMed Web of Science ®Google Scholar
• Bungert J., Engel J. D. The role of transcription factors in erythroid development. Ann. Med. 1996; 28: 47–55
   PubMed Web of Science ®Google Scholar
• Stamatoyannopoulos J. A., Goodwin A., Joyce T., Lowrey C. H. NF-E2 and GATA binding motifs are required for the formation of DNase I hypersensitive site 4 of the human β-globin locus control region. EMBO J. 1995; 14: 106–116
   PubMed Web of Science ®Google Scholar
• Trentesaux C., Ngo Nyoung M., Aries A., Morceau F., Ronchi A., Ottolenghi S., Jardillier J. C., Jeannesson P. Increased expression of GATA-1 and NF-E2 ery-throid-specific transcription factors during aclacinomycin-mediated differentiation of human erythroleukemic cells. Leukemia 1993; 1: 452–457
   Google Scholar
• Aries A., Trentesaux C., Ottolenghi S., Jardillier J. C., Jeannesson P., Doubeikovski A. Activation of erythroid-specific promoters during anthracycline-induced differentiation of K562 cells. Blodd 1996; 87: 2885–2890
   PubMed Web of Science ®Google Scholar
• Taxman D. J., Wojchowski D. M. Erythropoietin-induced transcription at the murine βmaj-globin promoter. J. Biol. Chem. 1995; 12: 6619–6627
   Google Scholar
• Miller I. J., Bieker J. J. A novel erythroid cell-specific murine transcription factor that binds to the CACCC element and is related to the Kriippel family of nuclear proteins. Mol. Cell. Biol. 1993; 13: 2776–2786
   PubMed Web of Science ®Google Scholar
• Nicolis S., Bertini C., Ronchi A., Crotta S., Lanfranco L., Moroni E., Giglioni B., Ottolenghi S. An erythroid specific enhancer upstream to the gene encoding the cell-type specific transcription factor GATA-1. Nucleic Acids Res. 1991; 19: 5285–5291
   PubMed Web of Science ®Google Scholar
• Seth A., Robinson L., Thompson D. M., Watson D. K., Papas T. S. Transactivation of GATA-1 promoter with ETS1, ETS2 and ERGB/HU-FLI-l proteins: stabilization of the ETSl protein binding on GATA-1 promoter sequences by monoclonal antibody. Oncogene 1993; 8: 1783–1790
   PubMed Web of Science ®Google Scholar
• Busfield S. I., Spadaccini A., Riches K. J., Tilbrook P. A., Klinken S. P. The major erythroid DNA-binding protein GATA-1 is stimulated by erythropoietin but not by chemical inducers of erythroid differentiation. Eur. J. Biochem. 1995; 230: 475–480
   PubMedGoogle Scholar
• Morceau F., ChÉNais B., Gillet R., Jardillier J. C., Jeannesson P., Trentesaux C. Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human ery-throleukemic cells. Cell Growth Differ. 1996; 7: 1023–1029
   PubMedGoogle Scholar
• Brewer G., Ross J. Regulation of c-myc RNA stability in vitro by a labile destabilizer with an essential nucleic acid component. Mol. Cell. Biol. 1989; 9: 1996–2006
   PubMed Web of Science ®Google Scholar
• Kiledjian M., Wang X., Liebhaber S. A. Identification of two KH domain proteins in the a-globin mRNP stability complex. EMBO J. 1995; 14: 4357–4364
   PubMed Web of Science ®Google Scholar
• Russell J. E., Liebhaber S. A. The stability of human β-globin mRNA is dependent on structural determinants positioned within its 3′ untranslated region. Blood 1996; 87: 5314–5323
   PubMed Web of Science ®Google Scholar
• Peterson M. G., Tupy J. L. Transcription factors: a new frontier in pharmaceutical development?. Biochem. Pharmacol. 1994; 47: 127–128
   PubMed Web of Science ®Google Scholar